Anemia and Iron Deficiency in Heart Failure

作者：Arora Natasha P; Ghali Jalal K^*

来源：Heart Failure Clinics, 2014, 10(2): 281-+.

DOI：10.1016/j.hfc.2013.11.002

• Anemia
• Iron deficiency
• Heart failure
• Iron therapy
• Erythropoiesis-stimulating agents

Anemia is a common comorbidity in patients with heart failure (HF) and is associated with poor prognosis. Iron deficiency, with or without anemia, confers increased risk of mortality and morbidity. Along with the altered iron metabolism in HF patients, inflammation creates challenges in the interpretation of laboratory parameters used to diagnose anemia in HF. Since the RED-HF trial failed to demonstrate any benefit from the use of erythropoiesis-stimulating agents (ESAs) on mortality or morbidity in HF patients, ESAs are no longer considered a treatment option, although intravenous iron has potential as therapy for anemic and nonanemic HF patients.

• 出版日期2014-4